Angiosarcoma of the thoracic wall responded well to nanoparticle albumin-bound paclitaxel: A case report

Drug Discov Ther. 2016;10(2):114-6. doi: 10.5582/ddt.2016.01005. Epub 2016 Feb 15.

Abstract

An 81-year-old woman visited a local clinic due to chest pain and a skin induration on the right precordia. She had a history of right breast cancer, and she had undergone a mastectomy and radiation therapy 10 years prior. Computed tomography (CT) imaging of the chest demonstrated a lobular mass that involved the right anterior thoracic wall and partially extruded from the thoracic cavity into the subcutaneous tissue. The tumor was surgically excised, and pathological analyses yielded a diagnosis of angiosarcoma. Five months after the operation, CT imaging showed multiple masses on the right pleura, indicating a local relapse and pleural dissemination of the angiosarcoma. Systemic chemotherapy composed of nanoparticle albumin-bound paclitaxel (nab-PTX) (80 mg/m(2)) was delivered weekly. After 4 courses of chemotherapy, the tumors regressed remarkably. Nab-PTX may be an effective treatment option for recurrent or metastatic angiosarcoma.

Publication types

  • Case Reports

MeSH terms

  • Aged, 80 and over
  • Albumin-Bound Paclitaxel / administration & dosage
  • Albumin-Bound Paclitaxel / therapeutic use*
  • Albumins / chemistry
  • Antineoplastic Agents, Phytogenic / administration & dosage
  • Antineoplastic Agents, Phytogenic / therapeutic use*
  • Female
  • Hemangiosarcoma / drug therapy*
  • Hemangiosarcoma / pathology
  • Humans
  • Pleura / pathology
  • Thoracic Neoplasms / drug therapy*
  • Thoracic Neoplasms / pathology
  • Thoracic Wall
  • Tomography, X-Ray Computed
  • Treatment Outcome

Substances

  • Albumin-Bound Paclitaxel
  • Albumins
  • Antineoplastic Agents, Phytogenic